{
  "pmcid": "10364744",
  "sha256": "ffb196da213a3a931c4b2fe85b272360e1d0e67c6d29e9ce38bf7e0f634175f3",
  "timestamp_utc": "2025-11-09T23:05:59.687691+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.697645933014353,
    "reading_ease": 22.636574162679466,
    "word_count": 275
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Prucalopride for Postoperative Ileus in Elective Colorectal Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicentre, double-blind, parallel, placebo-controlled randomised trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible patients were adults undergoing elective colorectal resection, excluding those with inflammatory bowel disease or planned ileostomy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to receive 2 mg prucalopride or placebo, administered 2 hours before surgery and daily for up to 6 days postoperatively."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assessed the effect of prucalopride, a selective serotonin-4-receptor agonist, on gut motility."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was time to GI-2, defined as passage of stool and tolerance of diet."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment by an external pharmacy."
      },
      "Blinding": {
        "score": 3,
        "evidence": "All participants, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 148 patients were randomised, 74 per group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "analysed using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "There was no significant difference in median time to GI-2 between prucalopride and placebo groups: 3.5 versus 4 days (P = 0.124)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with no significant differences in complications or readmission rates."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02947269."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}